Medical News
American
Medical News for 21 October 2018
Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer
EurekAlert! - 21 Oct 2018 08:00
(European Society for Medical Oncology) Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (P...
Global
Great Britain
Indian
South Africa